Company Focus
Sun Pharmaceuticals
Latest Sun Pharmaceuticals News
Biosimilars
US tariffs have served as a significant catalyst for Indian pharmaceutical companies to reassess their strategies, leading to accelerated efforts in market and product diversification. The challenging environment has encouraged a strategic shift towards higher margin products, reports The Pharma Letter’s India correspondent. 31 July 2025
Related News
Insights
Company Spotlight
A Swiss biotech company focussed on antibody discovery and development.
Latest News & Features of interest to Sun Pharmaceuticals
Pharmaceutical
Japanese drugmaker Eisai today announced that its in-house-discovered and developed orexin receptor antagonist Dayvigo (brand name in China: “达卫可®“ generic name: lemborexant) has launched in China for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. 18 August 2025
Pharmaceutical
Privately-held dermatology specialist LEO Pharma today revealed robust growth and significantly improved profitability, enabling an increase to the financial outlook for sales growth and adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) margin in first-half 2025 towards the upper-end of previously communicated expectations. 18 August 2025
Pharmaceutical
Australia’s Neurizon Therapeutics saw its shares rise 10% to A$0.16 today. after it revealed that it has been informed by the US Food and Drug Administration (FDA) that the decision on its Clinical Hold Complete Response (CHCR) to the Investigational New Drug (IND) application for NUZ-001, the company’s lead investigational therapy for amyotrophic lateral sclerosis (ALS), is now expected by October 3, 2025. 18 August 2025
Pharmaceutical
Brazil’s Fiocruz, through the Drug Technology Institute (Farmanguinhos), and the pharmaceutical company EMS have signed two unprecedented partnership agreements for the production of liraglutide and semaglutide, during an event in Brasília. 18 August 2025
Pharmaceutical
AstraZeneca has launched FluMist Home, the first FDA-approved influenza vaccine program that allows self- or caregiver administration. FluMist (influenza vaccine live, intranasal) can now be delivered directly to households, making it the first seasonal flu shot available without a trip to the clinic or pharmacy. 18 August 2025
Pharmaceutical
Last week, PureTech Health spun out a new company, Celea Therapeutics, which will develop its pulmonary fibrosis candidate deupirfenidone (LYT-100). The US Food and Drug Administration (FDA) granted approval for Insmed’s Brinsupri (brensocatib) for the treatment of a chronic inflammatory lung condition. Last week also saw US biotech Sarepta Therapeutics selling 9.3 million shares in Arrowhead, raising around $174 million, and transferring around $50 million to Arrowhead. Basilea in-licensed rights to Venatorx’ urinary tract infection candidate ceftibuten-ledaborbactam etzadroxil. 17 August 2025
Pharmaceutical
Denmark’s Novo Nordisk scored a significant regulatory win for GLP-1 drug Wegovy (semaglutide), as the US Food and Drug Administration (FDA) has approved an additional indication for the drug. 16 August 2025
Pharmaceutical
Costco has confirmed it will not sell the abortion pill mifepristone, which is sold under the Mifeprex brand, in any of its US pharmacy locations. The decision comes after pressure from faith-based advocacy groups including Alliance Defending Freedom. With Costco’s stance set, these groups are now focusing on CVS and Walgreens. 15 August 2025
Pharmaceutical
The Swiss government has met with senior executives from Roche and Novartis to discuss the outlook for the pharmaceutical industry amid escalating US trade measures. 15 August 2025
Pharmaceutical
The US Department of Health and Human Services has reinstated the Task Force on Safer Childhood Vaccines, a panel created by Congress to strengthen the safety, quality and oversight of vaccines given to American children. The original group was disbanded in 1998. 15 August 2025
Latest In Brief for Sun Pharmaceuticals
Pharmaceutical
Japan’s Mochida Pharmaceutical has announced that Lialda (mesalazine 600mg)the will be launched on September 8, 2025, as the NHI (National Health Insurance) Drug Price was listed on August 14, 2025. 18 August 2025
Relevant Ones To Watch News
Last week, PureTech Health spun out a new company, Celea Therapeutics, which will develop its pulmonary fibrosis candidate deupirfenidone (LYT-100). The US Food and Drug Administration (FDA) granted approval for Insmed’s Brinsupri (brensocatib) for the treatment of a chronic inflammatory lung condition. Last week also saw US biotech Sarepta Therapeutics selling 9.3 million shares in Arrowhead, raising around $174 million, and transferring around $50 million to Arrowhead. Basilea in-licensed rights to Venatorx’ urinary tract infection candidate ceftibuten-ledaborbactam etzadroxil. 17 August 2025
29 July 2025
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze